Digital pathology solutions are increasingly used in the preclinical and clinical development phases, particularly toxicologic pathology and clinical trials, speeding up the process and curtailing expenses. SAN ANTONIO, Feb. 15,...

Partnership to provide access to Flagship’s AI-aided software for quantifying PD-L1 IHC stains across various tissue types NEW YORK & BROOMFIELD, Colo.--(BUSINESS WIRE)--Paige,the global leader in AI-based diagnostic software in...

With its unique cTA® and data-driven decision support platform, Flagship offers its pharmaceutical partners robust, actionable data for informed decision making during clinical development SANTA CLARA, Calif., Sept. 18, 2018 /PRNewswire/...

Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue...

Flagship Biosciences has introduced a new menu of services to help drug developers more confidently define their path to success. ActionAssays is a comprehensive catalog of brightfield immunohistochemistry (IHC) assays that provide actionable...

Westminster, CO – April 5, 2015 – Since 2009, Flagship Biosciences has grown to become recognized as the clear industry leader in the delivery of precision pathology reports quantifying a given endpoint in digital pathology. These reports...